Clinical Trials Logo

Clinical Trial Summary

To evaluate the tolerability, acceptability and potential effect size of the efficacy of 4 months of atomoxetine treatment for patients with co-occurring ATS and heroin dependence (COATS) receiving buprenorphine maintenance treatment (BMT) and educational drug and HIV risk reduction counseling (EDRC).


Clinical Trial Description

The Specific Aims of the proposed study are:

1. To evaluate the tolerability, acceptability and potential effect size of the efficacy of 4 months of atomoxetine treatment for patients with co-occurring ATS and heroin dependence (COATS) receiving buprenorphine maintenance treatment (BMT) and educational drug and HIV risk reduction counseling (EDRC).

2. To better characterize patients with co-occurring ATS and heroin dependence (with regard to disturbances of mood, impulse control, executive functioning and patterns of drug use during MMT) and to evaluate the effects of atomoxetine on mood, impulsivity, and executive functioning (including attention, concentration, memory, and decision-making characteristics).

3. To provide training in drug abuse treatment, HIV prevention and treatment, and drug abuse clinical research to drug abuse clinical researchers and clinicians in Kota Bharu, Malaysia. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01863251
Study type Interventional
Source Yale University
Contact
Status Completed
Phase Phase 2
Start date May 2013
Completion date September 2014

See also
  Status Clinical Trial Phase
Terminated NCT03538444 - Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder N/A
Completed NCT01690546 - Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence Phase 2
Completed NCT01389167 - Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia Phase 3
Completed NCT01442493 - Reengineering Methadone Treatment Study of Patient-centered Methadone Treatment N/A
Completed NCT01182402 - Electronic Compliance Monitoring in Opioid Substitution Treatment N/A
Completed NCT00634803 - Clinical Trial of Integrated Treatment for Pain and Opioid Dependence Phase 1/Phase 2
Completed NCT00987961 - Linking Hospitalized Injection Drug Users to Buprenorphine Phase 3
Completed NCT00757744 - Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China Phase 3
Completed NCT00577408 - Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone Phase 3
Completed NCT00539123 - Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia N/A
Completed NCT00566969 - Cocaine Withdrawal and Pharmacotherapy Response N/A
Recruiting NCT00241930 - Integrating Buprenorphine Into HIV Treatment Phase 4
Completed NCT00218621 - The Effects of Methadone and Buprenorphine on Fetal Neurobehavior and Infant Neonatal Abstinence Syndrome - 1 Phase 2
Completed NCT00406484 - Brief Introductory Therapy for Opioid Dependence Phase 2
Completed NCT00580827 - Clinical Efficacy of Disulfiram in LAAM-Maintained Cocaine Abusers N/A
Completed NCT03015597 - Pilot Study of Contingency Management for Smoking Cessation N/A
Completed NCT01393392 - Developing a Smoking Cessation Intervention for Methadone Maintained Smokers Phase 1
Completed NCT01416584 - A Bridge to Treatment: The Therapeutic Workplace and Methadone Treatment N/A
Recruiting NCT00439049 - Substance Abuse Pre-Treatment Screening Study
Withdrawn NCT00398008 - HIV Risk Reduction and Drug Abuse Treatment in Iran Phase 2